Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update


- Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma -

Continued here:
Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Related Posts